(MedPage Today) — More diversity in clinical trials and health workforce needed
Category: News
NEI to discuss research advances in regenerative medicine for eye disease at ARVO 2016
The National Eye Institute (NEI), part of NIH, is participating in the Inaugural Press Conference from the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2016), the largest gathering of eye and vision researchers in the world…
Ora®がデビッド・ホランダー医師（M.D.、M.B.A.）を最高医学責任者（CMO）に任命
ボストン–(BUSINESS WIRE)–（ビジネスワイヤ） — 眼科用医薬品・医療機器の開発における世界一流パートナーのOra, Inc.は本日、デビッド・A・ホランダー医師（M.D.、M.B.A.）を最高医学責任者（CMO）兼シニアバイスプレジデントに任命したと発表しました。ホランダー医師は最近までアラガンの治療領域責任者兼臨床開発担当バイスプレジデントを務め、前眼部疾患とコンシューマーアイケアの分野における世界戦略および臨床開発プログラムの責任を負っていました。 Oraの社長兼最高経営責任者（CEO）であるスチュアート・B・エーブルソンは、次のように述べています。「Oraの技術、業務手法、有能なチームが、当社がその卓越性の評価を確立する上で極めて重大な役割を果たしてきました。ホランダー医師がOraにもたらす視点、経験、スキルは、当社顧客の大小の開発プログラムのあらゆる段階に対し格別の価値を提供する当社の能力を強化するものです。」 ハーバード大学眼科教授で外科医のマーク・エーブルソン医師が創設したOraが35年以上にわたり使命としているのは、眼科における臨床研究の質と再現性
12-month data highlight the safety and efficacy of ab-interno canaloplasty in primary open-angle glaucoma
Ellex Medical Lasers Ltd is pleased to announce findings from a 12-month case series review of 228 patients with primary open-angle glaucoma (POAG) which show that ab-interno canaloplasty (ABiC)…
NightstaRx reports long-term benefits of gene therapy for inherited form of progressive blindness
NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announced the publication from the University of Oxford of promising…
D.C. Week: Medicare Reforms Backed Up With New Rules
(MedPage Today) — Also, FDA approval for the first generic version of Crestor
Novel gene therapy can treat pulmonary hypertension linked with heart failure
Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, MD, Professor of Medicine…
Ora® nomeia Dr. David Hollander, mestre em Administração de Negócio, como diretor médico
BOSTON, EUA–(BUSINESS WIRE)–Ora, Inc., a principal parceira mundial de desenvolvimento farmacêutico e de dispositivos oftalmológicos, anunciou hoje a nomeação do Dr. David A. Hollander, mestre em Administração de Negócio (M.B.A.), como diretor médico e vice-presidente sênior. Dr. Hollander trabalhou recentemente como diretor da área terapêutica e vice-presidente de desenvolvimento clínico na Allergan®, responsável pelos programas estratégicos globais e de desenvolvimento clínico no segmento o
Scientists find way to reduce need for secondary cataract surgery
Scientists at the University of East Anglia may have found a way to prevent complications from surgery to treat cataract – the world’s leading cause of blindness.
Ora® designa a David Hollander, M.D., M.B.A., como Director Médico Ejecutivo
BOSTON–(BUSINESS WIRE)–Ora, Inc., el socio líder mundial de los productos farmacéuticos oftalmológicos y desarrollo de dispositivos, anunció hoy la designación de David A. Hollander, M.D., M.B.A., como Director Médico Ejecutivo y Vicepresidente Ejecutivo. El Dr. Hollander recientemente se desempeñó como Director del Área Terapéutica y Vicepresidente de desarrollo clínico en Allergan®, responsable de los programas de estrategia global y desarrollo clínico en oftalmología del segmento anterior
Ora® nomme David Hollander, M.D., M.B.A., des services médicaux
BOSTON–(BUSINESS WIRE)–Ora, Inc., le principal partenaire mondial pour le développement de dispositifs et produits pharmaceutiques ophtalmiques, a annoncé aujourd’hui la nomination de David A. Hollander, M.D., M.B.A., au poste de chef des services médicaux et premier vice-président. Le Dr Hollander a récemment servi comme chef du domaine thérapeutique et vice-président du développement clinique à Allergan®, responsable de la stratégie globale et des programmes de développement clinique dans l
Femto Trial Results Awaited From Cataract Surgery Meeting
New findings from a prospective randomized trial comparing femtosecond laser-assisted cataract surgery with traditional phacoemulsification will be presented at the upcoming symposium. Medscape Medical News
Ora® ernennt Dr. med. David Hollander, M.B.A., zum Chief Medical Officer
BOSTON–(BUSINESS WIRE)–Ora, Inc., der weltweit führende Partner bei der Entwicklung von augenheilkundlichen pharmazeutischen und technischen Produkten, meldete heute die Ernennung von Dr. med. David A. Hollander, M.B.A., zum Chief Medical Officer und Senior Vice-President. Dr. Hollander war zuletzt Therapeutic Area Head und Vice President für klinische Entwicklung bei Allergan® und in dieser Stellung für die globale Strategie und klinischen Entwicklungsprogramme in der Ophthalmologie des vord
Riassunto: Ora® sceglie il Dr. David Hollander, M.B.A., come direttore medico
BOSTON–(BUSINESS WIRE)–Ora, Inc., il principale partner mondiale per lo sviluppo di dispositivi e prodotti farmaceutici nel settore oftalmico, ha oggi annunciato la nomina a vicepresidente senior e direttore medico del dottor David A. Hollander, M.B.A. Negli ultimi anni il Dr. Hollander ha ricoperto la carica di responsabile del settore terapeutico e di vicepresidente dello sviluppo clinico presso Allergan®, in qualità di responsabile della strategia globale e dei programmi di sviluppo clinic
Ora® Appoints David Hollander, M.D., M.B.A., as Chief Medical Officer
BOSTON–(BUSINESS WIRE)–Ora® APPOINTS DAVID HOLLANDER, M.D., M.B.A., AS CHIEF MEDICAL OFFICER
Endophthalmitis Rare in Intravitreal Injections
Endophthalmitis occurs infrequently after intravitreal injection, and vision can usually be preserved if physicians are vigilant, researchers found. Medscape Medical News
American Society of Cataract and Refractive Surgery (ASCRS) 2016 Symposium
Read clinically focused news coverage of key developments from ASCRS 2016. Medscape Ophthalmology
Diabetic patients at risk for developing retinal diabetic neuropathy
A University of Iowa-led study of diabetes-related vision impairment holds good news — and some bad news — for patients with signs of these disorders.
ZOTEN nanoparticles can help develop natural immunity against genital herpes
An effective vaccine against the virus that causes genital herpes has evaded researchers for decades. But now, researchers from the University of Illinois at Chicago working with scientists from Germany have shown that zinc-oxide nanoparticles shaped l…
Reader Poll: Corneal Crosslinking for Keratoconus
Corneal crosslinking has been available in Europe and throughout the world for a decade, and it is now available in the United States. Will you adopt this newly approved procedure for keratoconus? Medscape Medical News